{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:09:00Z","timestamp":1785863340750,"version":"3.56.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rbmojournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive BioMedicine Online"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.rbmo.2019.04.002","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T11:28:13Z","timestamp":1554895693000},"page":"522-529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Anti-M\u00fcllerian hormone as a diagnostic tool for PCOS under different diagnostic criteria in an unselected population"],"prefix":"10.1016","volume":"39","author":[{"given":"Gurkan","family":"Bozdag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezcan","family":"Mumusoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhal Yapici","family":"Coskun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Yarali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent Okan","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rbmo.2019.04.002_bib0001","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/humrep\/dev131","article-title":"The phenotypic diversity in per-follicle anti-Mullerian hormone production in polycystic ovary syndrome","volume":"30","author":"Alebic","year":"2015","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0002","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1210\/jc.2009-0839","article-title":"Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age","volume":"94","author":"Alsamarai","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0003","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1210\/jc.2006-0178","article-title":"Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline","volume":"91","author":"Azziz","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0004","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/humrep\/dey087","article-title":"Maternal polycystic ovarian syndrome and early offspring development","volume":"33","author":"Bell","year":"2018","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0005","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/humrep\/dew218","article-title":"The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"31","author":"Bozdag","year":"2016","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0006","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4158\/EP15903.OR","article-title":"Amh Measurement Versus Ovarian Ultrasound in the Diagnosis of Polycystic Ovary Syndrome in Different Phenotypes","volume":"22","author":"Carmina","year":"2016","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0007","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1210\/jc.2008-1231","article-title":"Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome","volume":"93","author":"Catteau-Jonard","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0008","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejogrb.2016.10.001","article-title":"Polycystic ovary syndrome and endometrial hyperplasia: an overview of the role of bariatric surgery in female fertility","volume":"207","author":"Charalampakis","year":"2016","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0009","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1093\/humrep\/der338","article-title":"Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome","volume":"26","author":"Cinar","year":"2011","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0015-0282(01)02944-2","article-title":"Relationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women","volume":"77","author":"Cook","year":"2002","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0011","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.clinbiochem.2016.08.005","article-title":"Performance characteristics of the Access AMH assay for the quantitative determination of anti-Mullerian hormone (AMH) levels on the Access* family of automated immunoassay systems","volume":"49","author":"Demirdjian","year":"2016","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0012","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1093\/humrep\/der297","article-title":"Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries","volume":"26","author":"Dewailly","year":"2011","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0013","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12958-015-0134-9","article-title":"Role of Anti-Mullerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review","volume":"13","author":"Dumont","year":"2015","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0014","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/humrep\/des213","article-title":"Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?","volume":"27","author":"Eilertsen","year":"2012","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/humrep\/15.1.24","article-title":"Women with polycystic ovary syndrome gain regular menstrual cycles when ageing","volume":"15","author":"Elting","year":"2000","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0016","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/humrep\/deg042","article-title":"Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3","volume":"18","author":"Fanchin","year":"2003","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0017","doi-asserted-by":"crossref","first-page":"E1649","DOI":"10.1210\/jc.2011-3133","article-title":"Differential regulation of ovarian anti-mullerian hormone (AMH) by estradiol through alpha- and beta-estrogen receptors","volume":"97","author":"Grynberg","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0018","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.fertnstert.2017.11.017","article-title":"Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome","volume":"109","author":"Guedikian","year":"2018","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0019","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1210\/jc.2014-3886","article-title":"The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage","volume":"100","author":"Hart","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0020","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1530\/EC-17-0129","article-title":"Polycystic ovary syndrome and the risk of obstructive sleep apnea: a meta-analysis and review of the literature","volume":"6","author":"Helvaci","year":"2017","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0021","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1210\/jc.2013-1393","article-title":"Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data","volume":"98","author":"Iliodromiti","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0022","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/apt.14058","article-title":"Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease","volume":"45","author":"Kim","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0023","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/humrep\/det469","article-title":"The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone","volume":"29","author":"Lauritsen","year":"2014","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0024","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1210\/jc.2003-030932","article-title":"Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age","volume":"89","author":"Laven","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0025","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1093\/humrep\/dew248","article-title":"Comparative evaluation of three new commercial immunoassays for anti-Mullerian hormone measurement","volume":"31","author":"Li","year":"2016","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0026","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1093\/humrep\/der302","article-title":"Clinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40","volume":"26","author":"Liang","year":"2011","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0027","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/humrep\/dex226","article-title":"Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Mullerian hormone using cluster analysis","volume":"32","author":"Lie Fong","year":"2017","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0028","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1093\/humrep\/dep225","article-title":"The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome","volume":"24","author":"Nardo","year":"2009","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0029","article-title":"Evidence-based Methodology Workshop on Polycystic Ovary Syndrome","year":"2012","journal-title":"Executive summary,"},{"key":"10.1016\/j.rbmo.2019.04.002_bib0030","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1210\/jc.2006-1582","article-title":"Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries","volume":"92","author":"Pellatt","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0031","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0032","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cen.13517","article-title":"Anti-Mullerian hormone measurement for the diagnosis of polycystic ovary syndrome","volume":"88","author":"Sathyapalan","year":"2018","journal-title":"Clin. Endocrinol. (Oxf)."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0033","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.fertnstert.2007.02.014","article-title":"Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance","volume":"88","author":"Seifer","year":"2007","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0034","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cen.13795","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"89","author":"Teede","year":"2018","journal-title":"Clin. Endocrinol. (Oxf)."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0035","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/humrep\/dey256","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"33","author":"Teede","year":"2018","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0036","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1093\/humrep\/17.12.3065","article-title":"Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve","volume":"17","author":"van Rooij","year":"2002","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0037","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s10815-014-0300-6","article-title":"Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients","volume":"31","author":"Wiweko","year":"2014","journal-title":"J. Assist. Reprod. Genet."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0038","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/humrep\/des232","article-title":"Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria","volume":"27","author":"Yildiz","year":"2012","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0039","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.fertnstert.2017.10.018","article-title":"Metabolic syndrome, hypertension, and hyperlipidemia in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"109","author":"Yilmaz","year":"2018","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2019.04.002_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203129","article-title":"Threshold value of anti-Mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women","volume":"13,","author":"Yue","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.rbmo.2019.04.002_bib0041","series-title":"Polycystic Ovary Syndrome.","first-page":"377","article-title":"Diagnostic criteria for polycystic ovary syndrome: towards a rational approach","author":"Zawadzki","year":"1992"}],"container-title":["Reproductive BioMedicine Online"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648319303773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648319303773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:16:38Z","timestamp":1761466598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472648319303773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1472648319303773"],"URL":"https:\/\/doi.org\/10.1016\/j.rbmo.2019.04.002","relation":{},"ISSN":["1472-6483"],"issn-type":[{"value":"1472-6483","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-M\u00fcllerian hormone as a diagnostic tool for PCOS under different diagnostic criteria in an unselected population","name":"articletitle","label":"Article Title"},{"value":"Reproductive BioMedicine Online","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rbmo.2019.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}